Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report

Samankaltaisia teoksia

• Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
  Tekijä: Chigbu, DeGaulle I, et al.
  Julkaistu: (2015)
• Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
  Tekijä: Ayyappanavar, Shruti, et al.
  Julkaistu: (2021)
• Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
  Tekijä: Lakshey Dudeja, et al.
  Julkaistu: (2019-01-01)
• Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
  Tekijä: McLaurin, Eugene B., et al.
  Julkaistu: (2014)
• Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
  Tekijä: Dudeja, Lakshey, et al.
  Julkaistu: (2019)